Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

 
• By Sue Sutter

More than seven months after the Oncologic Drugs Advisory Committee voted that Pepaxto and Copiktra had negative benefit-risk profiles in their labeled indications, the drugs' approvals remain intact. Oncopeptides is still considering whether to heed the FDA's request to withdraw the Pepaxto NDA, even though the drug is not currently marketed. Secura Bio says Copiktra remains on the market and available for prescribing.

Thumbs down
Pepaxto and Copiktra were knocked down at a September ODAC meeting, but they're still not completely out. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews